Today: 7 February 2026
Subscribe
Browse Category

LSE:GSK News 11 December 2025 - 24 December 2025

GSK plc Stock: Latest News, Share Price Today, Analyst Forecasts and 2026 Outlook (December 24, 2025)

GSK plc Stock: Latest News, Share Price Today, Analyst Forecasts and 2026 Outlook (December 24, 2025)

GSK plc (LSE: GSK / NYSE: GSK) is heading into the year-end stretch with an unusually busy mix of policy headlines, regulatory wins, and capital-return updates—exactly the kind of combo that can make a “defensive” pharma stock behave a little less like a sleepy utility and a little more like… well, a stock that has catalysts. On Christmas Eve (Wednesday, December 24, 2025), liquidity is thinner than usual because both the London and U.S. markets run shortened hours. The London Stock Exchange closes early at 12:30 p.m. UK time, and the NYSE/Nasdaq close early at 1:00 p.m. ET. MoneyWeek+1 Below
24 December 2025
····
GSK plc Stock: Today’s News, Analyst Forecasts, and the Biggest Catalysts Heading Into 2026 (Dec. 22, 2025)

GSK plc Stock: Today’s News, Analyst Forecasts, and the Biggest Catalysts Heading Into 2026 (Dec. 22, 2025)

As of December 22, 2025, GSK plc (LSE: GSK / NYSE: GSK) is getting an unusually dense cluster of “headline risk + catalyst potential” — the kind of mix that can make a defensive pharma stock trade like it just drank three espressos. In the last two weeks alone, investors have had to price in: Below is the most complete, publication-ready breakdown of current GSK stock news, forecasts, and analyst takes available as of today, plus what to watch next. GSK stock price check On the NYSE, GSK’s American Depositary Shares (ADS) last traded around $48.61. (Each GSK ADS represents
22 December 2025
····
GSK plc Stock News and Forecast (Dec. 20, 2025): TrumpRx Pricing Deal, Exdensur FDA Approval, Buybacks, and Analyst Targets

GSK plc Stock News and Forecast (Dec. 20, 2025): TrumpRx Pricing Deal, Exdensur FDA Approval, Buybacks, and Analyst Targets

GSK plc (LSE: GSK; NYSE: GSK) heads into the weekend with a rare “everything-bagel” mix of catalysts: a new U.S. drug-pricing agreement tied to tariff relief, a fresh FDA approval that could reshape severe-asthma dosing schedules, expanding vaccine indications in Europe, and a steady drumbeat of buybacks. For investors tracking GSK stock, the headline isn’t just one event—it’s the way policy, pipeline, and capital returns are colliding in the same two-week window. Because December 20, 2025 is a Saturday, markets are closed. In U.S. trading, GSK’s ADR last closed on Friday, Dec. 19 at $48.61. StockAnalysis Below is a detailed
20 December 2025
·····
GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc

GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc

GSK plc (LSE: GSK; NYSE: GSK) is ending 2025 with a busy headline tape—exactly the kind of environment where investors tend to re-check both the “story” and the spreadsheet. On Thursday, December 18, 2025, GSK published a fresh share buyback update, while markets continue to digest a string of regulatory milestones across respiratory, vaccines, and infectious diseases that could shape the company’s growth profile into 2026. Below is what’s new as of 18.12.2025, what analysts are forecasting, and what matters most for GSK stock next. GSK stock snapshot on Dec. 18, 2025 In US trading, GSK’s ADR (NYSE: GSK) was
18 December 2025
····
GSK plc (GSK) news: FDA approves twice‑yearly asthma biologic Exdensur on Dec. 17, 2025

GSK plc (GSK) news: FDA approves twice‑yearly asthma biologic Exdensur on Dec. 17, 2025

GSK plc (GSK) announced today that the FDA approved Exdensur (depemokimab‑ulaa) for severe eosinophilic asthma in patients 12+. Here’s what it means for GSK’s respiratory pipeline, competition, and shareholders on 17.12.2025. GSK plc (LSE/NYSE: GSK) is in the spotlight on Wednesday, 17 December 2025, after the company confirmed US FDA approval for Exdensur (depemokimab‑ulaa)—a new twice‑yearly biologic for severe asthma—while also releasing its latest share buyback update through a regulatory filing. Investegate+1 Below is a full, reader-friendly rundown of all current GSK news items dated 17.12.2025, plus what they signal for patients, clinicians, and investors. Today’s GSK headlines (17.12.2025) 1)
17 December 2025
····
GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

Updated: 17 December 2025 GSK plc stock (LSE: GSK; NYSE: GSK) is in focus on Dec. 17 after a major U.S. regulatory win: the FDA approved Exdensur (depemokimab‑ulaa) for severe asthma—giving GSK a new, ultra‑long‑acting biologic that’s dosed just twice a year. The approval lands as the company approaches a leadership handover on Jan. 1, 2026, and as investors weigh whether GSK’s late‑2025 pipeline momentum can translate into durable earnings growth in 2026 and beyond. Reuters+2GSK+2 Below is a full, news-driven breakdown of what’s moving GSK stock today, the most important recent catalysts, and how current analyst forecasts and technical
17 December 2025
····
GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms

GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms

December 16, 2025 — GSK plc stock (LSE: GSK; NYSE: GSK) is firmly on investors’ radar today after a cluster of late-year regulatory catalysts across respiratory, vaccines, and infectious diseases — the kind of headline flow that can reshape sentiment around a large-cap biopharma even when quarterly earnings are weeks away. In the latest available market data, GSK’s US-listed ADR (NYSE: GSK) traded around $49.24 (latest trade time in the feed: Dec. 16, 2025 00:15 UTC). Meanwhile, in London, GSK shares most recently closed at 1,833.50p on Dec. 15, up 0.49% on the day, with the Financial Times’ market data
16 December 2025
···
GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead GSK plc stock (LSE: GSK, NYSE: GSK) is ending 2025 with a rare “cluster” of market-moving catalysts packed into the same two-week window: fresh U.S. regulatory momentum for a new antibiotic, European regulatory backing for multiple respiratory products, and an imminent FDA decision that could reshape GSK’s long-term outlook in severe asthma and nasal polyps. For investors, this isn’t just headline noise. It’s the kind of sequencing—approval decisions, label expansions, and portfolio reinforcement—that can change how analysts
15 December 2025
····
GSK plc Stock News Today (Dec. 13, 2025): EU and FDA Decisions Put Pipeline Momentum Back in Focus

GSK plc Stock News Today (Dec. 13, 2025): EU and FDA Decisions Put Pipeline Momentum Back in Focus

Updated: December 13, 2025 GSK plc (LSE: GSK, NYSE: GSK) is ending the week in the spotlight after a cluster of regulatory updates in Europe and the United States—exactly the kind of “catalyst stacking” that can shift the narrative around a big pharma stock from defensive dividend name to pipeline and launch execution story. Add in an active share buyback program, a clearly mapped dividend calendar, and an incoming CEO transition in early 2026, and GSK stock has plenty for investors to digest heading into year-end. GSK+3Reuters+3Reuters+3 As of the latest available quote, GSK’s U.S.-listed ADR was about $48.81, with
13 December 2025
····
GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

Published: 12 December 2025 GSK plc stock is back in focus on Friday as investors digest a fast-moving cluster of regulatory headlines across vaccines, infectious diseases and oncology—alongside ongoing buybacks and fresh consensus forecasts that map out how GSK’s revenue mix may evolve into 2031. On the New York Stock Exchange, GSK’s U.S.-listed ADR was trading around $48.88 in the latest available quote (prices move throughout the session). Below is a full, publication-ready roundup of the latest GSK stock news and market-moving developments available as of 12.12.2025, plus analyst forecasts and the key catalysts investors are watching into early 2026.
12 December 2025
······
GSK’s Emma Walmsley Hails US as ‘Best Place to Invest’ as UK Pharma Faces Tariffs, Rebate Cuts and a Fight for Jobs

GSK’s Emma Walmsley Hails US as ‘Best Place to Invest’ as UK Pharma Faces Tariffs, Rebate Cuts and a Fight for Jobs

On 11 December 2025, outgoing GSK chief executive Dame Emma Walmsley sent a stark message to Westminster and the City: for big drug makers, the United States is now the premier destination for investment – and Britain is at risk of slipping further behind. In a broadcast interview, Walmsley praised the US as the world’s most attractive market for new medicines, saying it remains the leading arena for launching innovative drugs and vaccines and the “best place to invest” for global pharma. She also pointed to China as the other key growth market for business development. The Guardian+1 Her comments
11 December 2025
···
GSK Stock (LON:GSK, NYSE:GSK): Latest News, FDA Catalysts and 2026 Outlook – December 11, 2025

GSK Stock (LON:GSK, NYSE:GSK): Latest News, FDA Catalysts and 2026 Outlook – December 11, 2025

GSK plc stock has quietly morphed from a problem child of Big Pharma into one of 2025’s more interesting “value with growth” stories. The shares are trading near multi‑year highs, the company has upgraded guidance, big litigation overhangs are easing, and a cluster of U.S. FDA decisions is about to test how much of that optimism is justified. As of last night’s close, GSK’s U.S. ADR finished at $48.40, up more than 45% year‑to‑date, while the London‑listed shares recently changed hands around 1,800p, having pushed above their 200‑day moving average of 1,547.73p on heavy volume. MarketBeat+1 Below is a deep
11 December 2025
····
1 2 3 4 5

Stock Market Today

Go toTop